Columbia Scientists Edit 3 Human Embryo Gene Targets, Fueling Designer-Baby Debate
Updated
Updated · The New York Times · Jun 11
Columbia Scientists Edit 3 Human Embryo Gene Targets, Fueling Designer-Baby Debate
3 articles · Updated · The New York Times · Jun 11
Summary
Columbia researchers said they used base editing to swap single DNA letters in human embryos, changing genes tied to fetal hemoglobin, cholesterol levels and heart-disease risk.
The work, still under peer review and unpublished, drew immediate debate over whether the technique moves medicine closer to preventing inherited disease or to selecting preferred traits.
Base editing is attracting attention partly because earlier embryo experiments with CRISPR produced major errors, including DNA rearrangements, missing segments and even destroyed chromosomes.
Clinicians backing the approach said it could eventually help families avoid passing on severe disorders such as Huntington’s disease or Duchenne muscular dystrophy by repairing embryos that might otherwise be discarded.
With biotech startups racing to create gene-edited babies, who will write the rules for the human race?
As gene editing becomes reality, how do we prevent the past horrors of eugenics from defining our future?
Human Embryo Base Editing in 2026: Scientific Advances, Clinical Potential, and the Ethics of Heritable Genome Editing
Overview
In June 2026, Columbia University achieved a major milestone by successfully applying base editing in human embryos, marking a crucial step toward safer and more precise gene-editing technologies. Unlike traditional methods, base editing enables highly accurate, single-base changes in DNA without cutting both strands, which minimizes cellular repair processes and reduces unpredictable outcomes or unwanted genetic changes. This advancement offers a potentially lower risk of genotoxicity, making it a promising approach for future therapeutic applications. Experts have recognized this as an exciting development, highlighting its importance in improving the safety of gene editing in human embryos.